Ultrasound in Hepatic Veno-occlusive Disease (HVOD) after Pediatric Hematopoietic Stem Cell Transplantation (HSCT): Comparison of Diagnostic Criteria Including the Pediatric Criteria of European Society for Blood and Marrow Transplantation (EBMT)

Pediatric Hematology and Oncology
Heeyoung ChungSeong-Koo Kim

Abstract

The European Society for Blood and Marrow Transplantation (EBMT) has recently announced new diagnostic criteria for pediatric hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). We retrospectively inspected 97 ultrasound exams of 60 pediatric HSCT patients, and compared its diagnostic value using the Baltimore, Seattle and pediatric EBMT criteria. Nine of the ten patients who were diagnosed as HVOD only in the EBMT criteria had severe or very severe HVOD. In the Seattle and EBMT criteria, portal vein velocity, peak systolic velocity and resistance index of hepatic artery, gallbladder wall thickening and ascites were statistically significant. No ultrasound variable showed significant association in the Baltimore criteria. All patients with portal vein velocity below 10 cm/s were in higher EBMT grade. A scoring system was developed, to evaluate the overall relationship of the ultrasound findings with the diagnosis of HVOD, showing fair (0.768 and 0.733) AUC in the ROC curve of EBMT and Seattle criteria.

References

Sep 1, 1992·Radiology·S C HommeyerG B McDonald
May 1, 1992·AJR. American Journal of Roentgenology·J HerbetkoG L Phillips
Jul 1, 1991·AJR. American Journal of Roentgenology·H K RosenbergR D Bellah
Apr 1, 1990·AJR. American Journal of Roentgenology·B P BrownR Gingrich
Jan 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G B McDonaldE D Thomas
Jun 1, 1995·AJR. American Journal of Roentgenology·S A TeefeyW D Middleton
Oct 10, 1997·Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine·M J SharafuddinD W Hunter
Jul 23, 2002·Transplantation·Nathalie LassauOlivier Hartmann
Oct 11, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kasiani C MyersSonata Jodele
Sep 15, 2015·Bone Marrow Transplantation·J C NaplesR S Bajwa
Aug 9, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Micah A SkeensUNKNOWN HSCT subgroup of the Pediatric Acute Lung Injury & Sepsis Investigators (PALISI)
May 29, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mutsumi NishidaTakanori Teshima

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.